Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous ...

Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc ...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...

G protein-coupled receptors (GPCRs) represent the largest family of membrane proteins and one of the most successful therapeutic targets in modern medicine, with approximately 34% of FDA-approved ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

Collaboration Combines Best-in-Class Biology with Agile AI and Chemistry Automation for Rapid Discovery of Better Molecules for Highly Valuable G Protein-Coupled Receptor (GPCR) Targets MENLO PARK, ...

A couple of analysts initiated coverage on Septerna, Inc. (NASDAQ:SEPN), which debuted on NASDAQ last month. Cantor analyst Josh Schimmer initiated coverage at an Overweight rating with a price target ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common gut bacteria can metabolize certain oral medications that target cellular ...